HypertensionPACEinMM-ONNCT02742597
Patient-Centred Innovations for Persons With Multimorbidity - Ontario
A study testing TIP / IMPACT Plus Care Coordination in people with Hypertension and Depression, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 9 sites in Canada.
Trial summary
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the patient in context; and realign the health care system from separate silos to coordinated… Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hypertension, Depression, Anxiety
- What is being tested?
- TIP / IMPACT Plus Care Coordination
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 175 participants
- Where
- 9 sitesCanada
- Study dates
- 12 Jan 2016to 19 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 3+ Chronic Conditions
- 18 to 80 years of age
- Eligible for TIP/IMPACT Plus program
- Must live in catchment area for TIP/IMPACT Plus program (Toronto, Ontario, Canada)
- Decision Makers: Responsible for policy and financial decisions related to the TIP / IMPACT Plus program
- TIP / IMPACT Providers: Providers that have delivered the TIP / IMPACT Plus intervention to at least one patient, including pharmacist, nurse, nurse practitioner, physiotherapist, social worker, dietitian, occupational therapist, personal care worker / home care coordinator
Show all 10Show fewer
- Family Physicians / Specialists: Those that take part in the TIP / IMPACT Plus intervention, including internist, psychiatrist, and family physician
- Patients: Need to meet the inclusion criteria of the TIP / IMPACT Plus program, 18 to 80 years of age, 3+ chronic conditions, and have received the intervention a minimum of 4 months prior to the qualitative interview
- Family and Caregivers: Need to be a family member or caregiver of a TIP / IMPACT Plus patient that has received the intervention a minimum of 4 months prior to the qualitative interview.
- Referral Provider: Emergency Department doctor, nurse practitioner, CCAC coordinator or representative community family doctor that has referred patients to the TIP / IMPACT Plus program.
Who cannot join
- Unable to reasonably respond to questionnaires or provide informed consent (ie. cognitive impairment or language barrier)
- Deemed by provider to be too fragile
- For Qualitative (Study 2.1):
- Decision Makers that are not knowledgeable about or involved with the TIP / IMPACT Plus program
- Providers/Family Physicians/Specialists that have not ever referred to or taken part in a TIP / IMPACT Plus intervention or have not been active with the program in the last year
- Family and Caregivers of Patients or Patients themselves that haven't yet received the TIP / IMPACT Plus intervention or those that received the intervention within the last 4 months
Trial locations and contacts
9 sites in 1 country.
9 sites in 1 country
Canada9 sites
Western University
London, Ontario, N6A 3K7
Mount Sinai Hospital
Toronto, Ontario
Providence Healthcare
Toronto, Ontario
St. Michael's Hospital
Toronto, Ontario
Sunnybrook Health Sciences Centre
Toronto, Ontario
Toronto Central Community Care Access Centre
Toronto, Ontario
Toronto East General Hospital
Toronto, Ontario
University Hospital Network
Toronto, Ontario
Women's College Hospital
Toronto, Ontario
About this study
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the patient in context; and realign the health care system from separate silos to coordinated collaborations in care. PACE in MM will propose multifaceted innovations in Chronic Disease Prevention and Management (CDPM) that will be grounded in current realities (i.e. Chronic Care Models including Self-Management Programs), that are linked to Primary Care (PC) reform efforts. The study will build on this firm foundation, will design and test promising innovations and will achieve transformation by creating structures to sustain relationships among researchers, decision-makers, practitioners, and patients. The Team will conduct inter-jurisdictional comparisons and is mainly a Quebec (QC) - Ontario (ON) collaboration with participation from 4 other provinces: British Columbia (BC); Manitoba (MB); Nova Scotia (NS); and New Brunswick (NB). The Team's objectives are: 1) to identify factors responsible for success or failure of current CDPM programs linked to the PC reform, by conducting a realist synthesis of their quantitative and qualitative evaluations; 2) to transform consenting CDPM programs identified in Objective 1, by aligning them to promising interventions on patient-centred care for multimorbidity patients, and to test these new innovations' in at least two jurisdictions and compare among jurisdictions; and 3) to foster the scaling-up of innovations informed by Objective 1 and tested/proven in Objective 2, and to conduct research on different approaches to scaling-up. This registration for Clinical Trials only pertains to Objective 2 of the study.
Read the detailed description
A recent systematic review on the prevalence of Multimorbidity (MM) recommended a count of 3+ chronic diseases, with no focus on any single chronic disease in particular. This definition identifies a more vulnerable population with higher needs, lower income or poverty, poorer outcomes and challenging processes of care. It includes people with a wide array of complexity from the uncomplicated course of minimally interacting chronic diseases to the highly complex MM patients. MM is not only important due to the burden on patients, but because it accounts for high utilization. The definition represents a continuum of vulnerability in which there are many opportunities for prevention and management. Despite the high prevalence of MM, most research and health care is still based on a single disease paradigm which may not be appropriate as 45% of primary care patients have MM. A recent Cochrane systematic review on the impact of interventions for patients with MM has identified a paucity of studies internationally with mixed results, thus paving the way for the work of this Team. The most promising intervention, to date, was enhanced teamwork in a multifaceted intervention involving multiple professionals.
Patient-Centred Partnerships between Patients and Providers: The definition of patient-centred partnerships is derived from Canadian policy reports: "collaboration between informed, respected patients and a healthcare team." There is an internationally accepted comprehensive operational definition with four components which will guide many aspects of the proposed research program: first, exploring the patients' diseases and the illness experience; second, understanding the whole person in context; third, finding common ground; and fourth, enhancing the patient-provider relationship. There is empirical evidence for the impact of patient centred partnerships on better patient outcomes and lower costs. Systematic reviews of interventions indicated promising results for feasible practice-based interventions targeting both providers and patients.
Canadian policy reports defined this second facet of patient-centredness, as "seamless coordination and integration of care." Transitions requiring coordination are a key feature of care for patients with MM. Coordination has been shown to positively impact: symptom relief; social functioning; hospital re-admission and related costs. Papers reviewed by this Team identified the most promising type of intervention to be structured delivery system re-design.
STUDY #2.1 Qualitative Evaluation of the Aligned Programs Purpose: The study will: assess how the aligned program performs; distinguish between components of the interventions; and identify contextual factors that may have influenced the content and effectiveness of the intervention. It will also examine the local barriers and facilitators as well as the transitions and coordination of care.
Methods and design: The Team will conduct a qualitative evaluation of the aligned program to explain how various contexts influence observed effects [1] including the context of the health care systems in each province. A recent example of this research approach in Canada is Best et al, 2012 [2]. Data will be obtained from interviews and written documents. In-depth interviews will be conducted among the six categories of stakeholders. This will include: a) decision-makers (n = 10); b) providers (n = 10); c) family physicians and specialists (n = 10); d) a purposive sample of patients with multimorbidity (n = 10); e) family and informal caregivers (n=10); and f) referral providers (n = 10) [51]. Number of interviews are estimates and will be guided by the saturation of data [3].
Data collection: In-depth interviews, lasting 30 to 60 minutes will ensure complete and detailed participation. The data collection will be held during the second year of the transformed program. The interview guides will examine how the context variables influence the effects and the elements that could potentially inform the development of future interventions. All interviews will be audiotaped and transcribed verbatim. Additionally, written documents will be collected (program team meeting summaries, a sample of 10 medical records or research records at each participating site, a checklist describing the fidelity of the intervention, all documents produced specifically for the intervention) to provide an in-depth understanding of the various contexts in which the interventions occurred.
Data analysis: The data will be analyzed using an iterative and interpretative approach [4]. The data from all participants will be examined through both independent and team analysis occurring in a concurrent manner to build and develop on the emerging themes. A coding template will be developed and edited as new themes emerge while others are reclassified or discarded. The data management software NVivo 9.0 [QSR Int. USA] will be used to organize the coded data and identify exemplar quotes reflecting the central themes. All written documents will undergo a content analysis using NVivo 9.0. The final step of the analysis will be the triangulation of the synthesis of the themes from the stakeholder participants and the content analysis of the documents.[3-4] STUDY #2.2: Evaluation of effects of the Aligned Programs Setting: The same consenting participating sites as described in study 2.1. The methods presented below are for one setting and will be duplicated in the second setting. Patients are referred to receive the services of these programs by their providers. The intervention the investigators are testing here is the aligned programs. Patients referred to these programs are new patients and have never been exposed to the intervention. In addition to the main reason for referral to the program, the referral form will also include eligibility details for the evaluation, including diagnoses.
Patient sample: Patients recruited for the study will be cognitively intact and literate and aged between 18 and 80 years of age. The upper limit of 80 years is to avoid recruiting patients at risk of being institutionalized or dependent during the follow-up. Patients will present at least three chronic conditions.
Methods and Design: Patients agreeing to participate will complete questionnaires at baseline (T1) collecting the socio-demographic data and baseline measures, which will be used to document equivalence between groups (groups are defined below). Effectiveness of the aligned programs will be assessed using three strategies.
- To measure short-term effects (4 months), a randomized controlled trial (RCT) design with a before/after arm will be used [5]. Eligible patients will be randomized after consent to receive either the intervention within a short period of time (Group A) or control (Group C); The before/after arm (Group B) will receive the intervention without being placed into the RCT, as their doctors have deemed them too fragile to risk randomization; Control participants (Group C) will receive a list of healthcare resources they may contact to assist with their care; questionnaires will be completed at baseline (T1), and 4 months post enrollment (Group C) or intervention (Group A \& B) (T2) for all study participants. This will constitute the short-term measure of effectiveness of the intervention.
- To measure the mid-term effects, the study participants will complete the same questionnaire 16 months post-enrollment (Group C) or intervention (Group A \& B) (T3).
- To measure mid-term (T3) and long-term effects (T4 after 2 years) on health services utilization and cost, study participants in Groups A and B will provide consent to give access to their health administrative (HA) data. A control Group D will be constituted using anonymized HA data. Patients will be matched for gender, age, region and three main diagnoses. The Team will build algorithms for matching every set of controls. Groups A and B together will be compared to this propensity matched control Group D using administrative (HA) data.
Variables and outcome measures: The variables fall into 5 categories: sociodemographic; PC context; main covariables of interest; primary outcomes; secondary outcomes. Sociodemographic characteristics include gender, age, education, family income, marital status, occupation, housing and number of persons living under the same roof. Context variables refer to type of PC organization in which the intervention occurs (solo or group practices, Family Health Team, Community Health Centre). The three main covariables of interest are the Team's three innovations: self-reported multimorbidity (measured by the Disease Burden Morbidity Assessment [6]; patient-centred partnership (Patient Perception of Patient-Centredness Scale [7-9]); and Patient centered coordination (the Patient Perceptions of Transitions in care, adapted by the investigators from Coleman [10]). The two primary outcome measures are the Health Education Impact Questionnaire (HeiQ) that provides a broad profile of the potential impacts of patient education interventions [11] and the level of perceived disease-management self-efficacy using the 6-item Self-Efficacy for Managing Chronic Disease (SEM-CD) [12]. Secondary patient perceived outcomes will be the VR-12 as a measure of health status and the EQ5D as a measure of Quality of Life [13]. The Kessler psychological distress scale K-6 will measure psychological distress [14]. The investigators will also use a questionnaire on health behaviors [15]. Finally, HA data will also be used as secondary outcomes to compare health care utilization and cost before and after the intervention. HA data will include emergency department visits, avoidable hospital admissions, readmissions, time to first primary care visit after emergency department visit and continuity of care.
Data analysis: The investigators will first describe participants' baseline characteristics in each group and compare among groups. To evaluate short-term effect, Groups A and C will be compared on T2 scores with an analysis of covariance (ANCOVA) adjusted for T1 scores [16]. To document mid-term effects, a before/after analysis of variance will be used to study the evolution of continuous variables collected 3 times [17]. Sub-analyses by gender will be performed. Health system costs in intervention and control groups will be evaluated by using amounts paid to providers based on provincial fee schedules and cost-weighted utilization of institutions including hospitals and long-term care. Utilization records obtained from HA data will be multiplied by applicable cost weights (e.g. CIHI Resource Intensity Weights - RIWs) and using CIHI costs per weighted case [18] The methods employed will model the individual patient-level costs incurred in the health system, using methods developed for costing using administrative data[19]. Incremental resources in the intervention group will be identified and costed using applicable time/resource inputs and relevant wage rates following guidelines for economic evaluation in health interventions [20].
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain, Arthritis, Rheumatoid Arthritis
- Being tested
- TIP / IMPACT Plus Care Coordination
- Medical subject headings
- Hypertension, Depression, Anxiety Disorders, Musculoskeletal Pain, Arthritis, Arthritis, Rheumatoid, Osteoporosis, Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TIP / IMPACT Plus Care CoordinationBehavioural
The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Active comparator | Intervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting Receives: Behavioral: TIP / IMPACT Plus Care Coordination |
| Group B | Active comparator | Before/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting Receives: Behavioral: TIP / IMPACT Plus Care Coordination |
| Group C | No intervention | Control group (n = 77) |
| Group D | No intervention | Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes
Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Transitions of Care
Patient Perception of Transitions of Care. Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Self-Efficacy
Self-Efficacy for Managing Chronic Disease Scale (SEM-CD). Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Patient-Centredness
Patient Perception of Patient-Centredness (PPPC). Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Secondary outcomes (7)
Evaluation of Intervention Effectiveness - Change in Chronic Diseases
Multimorbidity/Chronic Disease (MM-21): Score: Number of Chronic diseases
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Health Status
Health Status (VR-12): Score: Physical Component Summary (PCS) and the Mental Component Summary (MCS)
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Quality of Life
Quality of Life (EQ-5D-5L): Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Psychological Well-being
Psychological Well-being (Kessler 6 Scale). Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours
Lifestyle/Health Behaviours Questionnaire. Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Equity
Vertical Equity. Score: Mean
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Demographics
Demographics. Score: frequencies, means
Measured: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2016 (estimated)
- Study start12 Jan 2016
- Primary completion7 Apr 2019
- Study completion19 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 175 participants (actual)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Collaborators
- Western University, Canada, Université de Sherbrooke, Canadian Institutes of Health Research (CIHR), Sunnybrook Health Sciences Centre, Unity Health Toronto, University Health Network, Toronto, Michael Garron Hospital, Providence Healthcare, Mount Sinai Hospital, Canada, Toronto Central Community Care Access Centre, Women's College Hospital
- Responsible party
- Sponsor
- Investigators
- Moira Stewart, Principal investigator, Western University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02742597
- Sponsor's protocol ID
- 104191
- Acronym
- PACEinMM-ON
- Status last verified
- Sep 2020
- First submitted
- 21 Mar 2016
- Last updated
- 17 Mar 2023
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: De-identified subsets of data will be transferred upon request to healthcare providers at collaborating institutions under separate ethics approvals as/if required. Any transfers will be conducted by secure file transfer between encrypted devices. Any health information transferred will be de-identified.
Publications
Best A, Greenhalgh T, Lewis S, Saul JE, Carroll S, Bitz J. Large-system transformation in health care: a realist review. Milbank Q. 2012 Sep;90(3):421-56. doi: 10.1111/j.1468-0009.2012.00670.x.
PubMed 22985277Pawson, R. and N. Tilley, Realistic evaluation. London: Sage Publications Inc., 1997.
Patton, M.Q., Qualitative Research & Evaluation. 3rd ed. Thousand Oaks, CA: Sage Publications Inc., 2002.
Crabtree, B.F. and W.L. Miller, Doing Qualitative Research. Thousand Oaks, CA: Sage Publications Inc., 1999.
Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010 Aug;63(8):e1-37. doi: 10.1016/j.jclinepi.2010.03.004. Epub 2010 Mar 25.
PubMed 20346624Poitras ME, Fortin M, Hudon C, Haggerty J, Almirall J. Validation of the disease burden morbidity assessment by self-report in a French-speaking population. BMC Health Serv Res. 2012 Feb 14;12:35. doi: 10.1186/1472-6963-12-35.
PubMed 22333434Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, Jordan J. The impact of patient-centered care on outcomes. J Fam Pract. 2000 Sep;49(9):796-804.
PubMed 11032203Stewart M, Brown JB, Hammerton J, Donner A, Gavin A, Holliday RL, Whelan T, Leslie K, Cohen I, Weston W, Freeman T. Improving communication between doctors and breast cancer patients. Ann Fam Med. 2007 Sep-Oct;5(5):387-94. doi: 10.1370/afm.721.
PubMed 17893379Stewart, M., et al., The patient perception of patient-centeredness questionnaire (PPPC). Working Paper Series #04-1, April 2004.
Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure. Med Care. 2005 Mar;43(3):246-55. doi: 10.1097/00005650-200503000-00007.
PubMed 15725981Nolte S, Elsworth GR, Sinclair AJ, Osborne RH. The extent and breadth of benefits from participating in chronic disease self-management courses: a national patient-reported outcomes survey. Patient Educ Couns. 2007 Mar;65(3):351-60. doi: 10.1016/j.pec.2006.08.016. Epub 2006 Oct 5.
PubMed 17027221Sherer, M., et al., The self-efficacy scale: Construction and validation. Psychological Reports. 51: p. 663-671, 1982.
Rasanen P, Roine E, Sintonen H, Semberg-Konttinen V, Ryynanen OP, Roine R. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int J Technol Assess Health Care. 2006 Spring;22(2):235-41. doi: 10.1017/S0266462306051051.
PubMed 16571199Kessler RC, Barker PR, Colpe LJ, Epstein JF, Gfroerer JC, Hiripi E, Howes MJ, Normand SL, Manderscheid RW, Walters EE, Zaslavsky AM. Screening for serious mental illness in the general population. Arch Gen Psychiatry. 2003 Feb;60(2):184-9. doi: 10.1001/archpsyc.60.2.184.
PubMed 12578436Centers for Disease Control and Prevention (CDC), Behavioral Risk Factor Surveillance System Survey Questionnaire. 2007, Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention.
Study at a glance
From the registry record, last updated by the sponsor on 17 Mar 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patient-Centred Innovations for Persons With Multimorbidity - Ontario
- ClinicalTrials.gov ID
- NCT02742597
- Acronym / sponsor ID
- PACEinMM-ON / 104191
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain, Arthritis, Rheumatoid Arthritis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 175 participants (actual)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Collaborators
- Western University, Canada, Université de Sherbrooke, Canadian Institutes of Health Research (CIHR), Sunnybrook Health Sciences Centre, Unity Health Toronto, University Health Network, Toronto, Michael Garron Hospital, Providence Healthcare, Mount Sinai Hospital, Canada, Toronto Central Community Care Access Centre, Women's College Hospital
- Study start
- 12 Jan 2016 (actual)
- Primary completion
- 7 Apr 2019 (actual)
- Study completion
- 19 Oct 2022 (actual)
- First posted
- 19 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the patient in context; and realign the health care system from separate silos to coordinated collaborations in care. PACE in MM will propose multifaceted innovations in Chronic Disease Prevention and Management (CDPM) that will be grounded in current realities (i.e. Chronic Care Models including Self-Management Programs), that are linked to Primary Care (PC) reform efforts. The study will build on this firm foundation, will design and test promising innovations and will achieve transformation by creating structures to sustain relationships among researchers, decision-makers, practitioners, and patients. The Team will conduct inter-jurisdictional comparisons and is mainly a Quebec (QC) - Ontario (ON) collaboration with participation from 4 other provinces: British Columbia (BC); Manitoba (MB); Nova Scotia (NS); and New Brunswick (NB). The Team's objectives are: 1) to identify factors responsible for success or failure of current CDPM programs linked to the PC reform, by conducting a realist synthesis of their quantitative and qualitative evaluations; 2) to transform consenting CDPM programs identified in Objective 1, by aligning them to promising interventions on patient-centred care for multimorbidity patients, and to test these new innovations' in at least two jurisdictions and compare among jurisdictions; and 3) to foster the scaling-up of innovations informed by Objective 1 and tested/proven in Objective 2, and to conduct research on different approaches to scaling-up. This registration for Clinical Trials only pertains to Objective 2 of the study.
Detailed description
A recent systematic review on the prevalence of Multimorbidity (MM) recommended a count of 3+ chronic diseases, with no focus on any single chronic disease in particular. This definition identifies a more vulnerable population with higher needs, lower income or poverty, poorer outcomes and challenging processes of care. It includes people with a wide array of complexity from the uncomplicated course of minimally interacting chronic diseases to the highly complex MM patients. MM is not only important due to the burden on patients, but because it accounts for high utilization. The definition represents a continuum of vulnerability in which there are many opportunities for prevention and management. Despite the high prevalence of MM, most research and health care is still based on a single disease paradigm which may not be appropriate as 45% of primary care patients have MM. A recent Cochrane systematic review on the impact of interventions for patients with MM has identified a paucity of studies internationally with mixed results, thus paving the way for the work of this Team. The most promising intervention, to date, was enhanced teamwork in a multifaceted intervention involving multiple professionals.
Patient-Centred Partnerships between Patients and Providers: The definition of patient-centred partnerships is derived from Canadian policy reports: "collaboration between informed, respected patients and a healthcare team." There is an internationally accepted comprehensive operational definition with four components which will guide many aspects of the proposed research program: first, exploring the patients' diseases and the illness experience; second, understanding the whole person in context; third, finding common ground; and fourth, enhancing the patient-provider relationship. There is empirical evidence for the impact of patient centred partnerships on better patient outcomes and lower costs. Systematic reviews of interventions indicated promising results for feasible practice-based interventions targeting both providers and patients.
Canadian policy reports defined this second facet of patient-centredness, as "seamless coordination and integration of care." Transitions requiring coordination are a key feature of care for patients with MM. Coordination has been shown to positively impact: symptom relief; social functioning; hospital re-admission and related costs. Papers reviewed by this Team identified the most promising type of intervention to be structured delivery system re-design.
STUDY #2.1 Qualitative Evaluation of the Aligned Programs Purpose: The study will: assess how the aligned program performs; distinguish between components of the interventions; and identify contextual factors that may have influenced the content and effectiveness of the intervention. It will also examine the local barriers and facilitators as well as the transitions and coordination of care.
Methods and design: The Team will conduct a qualitative evaluation of the aligned program to explain how various contexts influence observed effects [1] including the context of the health care systems in each province. A recent example of this research approach in Canada is Best et al, 2012 [2]. Data will be obtained from interviews and written documents. In-depth interviews will be conducted among the six categories of stakeholders. This will include: a) decision-makers (n = 10); b) providers (n = 10); c) family physicians and specialists (n = 10); d) a purposive sample of patients with multimorbidity (n = 10); e) family and informal caregivers (n=10); and f) referral providers (n = 10) [51]. Number of interviews are estimates and will be guided by the saturation of data [3].
Data collection: In-depth interviews, lasting 30 to 60 minutes will ensure complete and detailed participation. The data collection will be held during the second year of the transformed program. The interview guides will examine how the context variables influence the effects and the elements that could potentially inform the development of future interventions. All interviews will be audiotaped and transcribed verbatim. Additionally, written documents will be collected (program team meeting summaries, a sample of 10 medical records or research records at each participating site, a checklist describing the fidelity of the intervention, all documents produced specifically for the intervention) to provide an in-depth understanding of the various contexts in which the interventions occurred.
Data analysis: The data will be analyzed using an iterative and interpretative approach [4]. The data from all participants will be examined through both independent and team analysis occurring in a concurrent manner to build and develop on the emerging themes. A coding template will be developed and edited as new themes emerge while others are reclassified or discarded. The data management software NVivo 9.0 [QSR Int. USA] will be used to organize the coded data and identify exemplar quotes reflecting the central themes. All written documents will undergo a content analysis using NVivo 9.0. The final step of the analysis will be the triangulation of the synthesis of the themes from the stakeholder participants and the content analysis of the documents.[3-4] STUDY #2.2: Evaluation of effects of the Aligned Programs Setting: The same consenting participating sites as described in study 2.1. The methods presented below are for one setting and will be duplicated in the second setting. Patients are referred to receive the services of these programs by their providers. The intervention the investigators are testing here is the aligned programs. Patients referred to these programs are new patients and have never been exposed to the intervention. In addition to the main reason for referral to the program, the referral form will also include eligibility details for the evaluation, including diagnoses.
Patient sample: Patients recruited for the study will be cognitively intact and literate and aged between 18 and 80 years of age. The upper limit of 80 years is to avoid recruiting patients at risk of being institutionalized or dependent during the follow-up. Patients will present at least three chronic conditions.
Methods and Design: Patients agreeing to participate will complete questionnaires at baseline (T1) collecting the socio-demographic data and baseline measures, which will be used to document equivalence between groups (groups are defined below). Effectiveness of the aligned programs will be assessed using three strategies.
- To measure short-term effects (4 months), a randomized controlled trial (RCT) design with a before/after arm will be used [5]. Eligible patients will be randomized after consent to receive either the intervention within a short period of time (Group A) or control (Group C); The before/after arm (Group B) will receive the intervention without being placed into the RCT, as their doctors have deemed them too fragile to risk randomization; Control participants (Group C) will receive a list of healthcare resources they may contact to assist with their care; questionnaires will be completed at baseline (T1), and 4 months post enrollment (Group C) or intervention (Group A \& B) (T2) for all study participants. This will constitute the short-term measure of effectiveness of the intervention.
- To measure the mid-term effects, the study participants will complete the same questionnaire 16 months post-enrollment (Group C) or intervention (Group A \& B) (T3).
- To measure mid-term (T3) and long-term effects (T4 after 2 years) on health services utilization and cost, study participants in Groups A and B will provide consent to give access to their health administrative (HA) data. A control Group D will be constituted using anonymized HA data. Patients will be matched for gender, age, region and three main diagnoses. The Team will build algorithms for matching every set of controls. Groups A and B together will be compared to this propensity matched control Group D using administrative (HA) data.
Variables and outcome measures: The variables fall into 5 categories: sociodemographic; PC context; main covariables of interest; primary outcomes; secondary outcomes. Sociodemographic characteristics include gender, age, education, family income, marital status, occupation, housing and number of persons living under the same roof. Context variables refer to type of PC organization in which the intervention occurs (solo or group practices, Family Health Team, Community Health Centre). The three main covariables of interest are the Team's three innovations: self-reported multimorbidity (measured by the Disease Burden Morbidity Assessment [6]; patient-centred partnership (Patient Perception of Patient-Centredness Scale [7-9]); and Patient centered coordination (the Patient Perceptions of Transitions in care, adapted by the investigators from Coleman [10]). The two primary outcome measures are the Health Education Impact Questionnaire (HeiQ) that provides a broad profile of the potential impacts of patient education interventions [11] and the level of perceived disease-management self-efficacy using the 6-item Self-Efficacy for Managing Chronic Disease (SEM-CD) [12]. Secondary patient perceived outcomes will be the VR-12 as a measure of health status and the EQ5D as a measure of Quality of Life [13]. The Kessler psychological distress scale K-6 will measure psychological distress [14]. The investigators will also use a questionnaire on health behaviors [15]. Finally, HA data will also be used as secondary outcomes to compare health care utilization and cost before and after the intervention. HA data will include emergency department visits, avoidable hospital admissions, readmissions, time to first primary care visit after emergency department visit and continuity of care.
Data analysis: The investigators will first describe participants' baseline characteristics in each group and compare among groups. To evaluate short-term effect, Groups A and C will be compared on T2 scores with an analysis of covariance (ANCOVA) adjusted for T1 scores [16]. To document mid-term effects, a before/after analysis of variance will be used to study the evolution of continuous variables collected 3 times [17]. Sub-analyses by gender will be performed. Health system costs in intervention and control groups will be evaluated by using amounts paid to providers based on provincial fee schedules and cost-weighted utilization of institutions including hospitals and long-term care. Utilization records obtained from HA data will be multiplied by applicable cost weights (e.g. CIHI Resource Intensity Weights - RIWs) and using CIHI costs per weighted case [18] The methods employed will model the individual patient-level costs incurred in the health system, using methods developed for costing using administrative data[19]. Incremental resources in the intervention group will be identified and costed using applicable time/resource inputs and relevant wage rates following guidelines for economic evaluation in health interventions [20].
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group A | Active comparator | Behavioral: TIP / IMPACT Plus Care CoordinationIntervention group (n = 86) Intervention: Participates in Telemedicine Impact Plus (TIP)/ IMPACT Plus Care Coordination meeting |
| Group B | Active comparator | Behavioral: TIP / IMPACT Plus Care CoordinationBefore/After Intervention group (n = 10) Intervention: Participates in TIP / IMPACT Plus Care Coordination meeting |
| Group C | No intervention | –Control group (n = 77) |
| Group D | No intervention | –Health Administrative Data Group (n = 430) Number of matched data controls. Not taking part in intervention. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- 3+ Chronic Conditions
- 18 to 80 years of age
- Eligible for TIP/IMPACT Plus program
- Must live in catchment area for TIP/IMPACT Plus program (Toronto, Ontario, Canada)
- Decision Makers: Responsible for policy and financial decisions related to the TIP / IMPACT Plus program
Key exclusion criteria (6 listed)
- Unable to reasonably respond to questionnaires or provide informed consent (ie. cognitive impairment or language barrier)
- Deemed by provider to be too fragile
- Decision Makers that are not knowledgeable about or involved with the TIP / IMPACT Plus program
- Providers/Family Physicians/Specialists that have not ever referred to or taken part in a TIP / IMPACT Plus intervention or have not been active with the program in the last year
- Family and Caregivers of Patients or Patients themselves that haven't yet received the TIP / IMPACT Plus intervention or those that received the intervention within the last 4 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TIP / IMPACT Plus Care CoordinationThe intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program. | Behavioural | Group A, Group B |
Primary outcome
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Health Education Impact Questionnaire (HeiQ). Score: Reliable improvement
Evaluation of Intervention Effectiveness - Change in Transitions of Care
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Patient Perception of Transitions of Care. Score: Mean
Evaluation of Intervention Effectiveness - Change in Self-Efficacy
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Self-Efficacy for Managing Chronic Disease Scale (SEM-CD). Score: Mean
Evaluation of Intervention Effectiveness - Change in Patient-Centredness
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Patient Perception of Patient-Centredness (PPPC). Score: Mean
7 secondary outcomes
Evaluation of Intervention Effectiveness - Change in Chronic Diseases
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Health Status
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Quality of Life
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Psychological Well-being
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Lifestyle/Health Behaviours
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Equity
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Evaluation of Intervention Effectiveness - Change in Demographics
Time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Mar 2023.
- Background: PubMed 22985277Best A, Greenhalgh T, Lewis S, Saul JE, Carroll S, Bitz J. Large-system transformation in health care: a realist review. Milbank Q. 2012 Sep;90(3):421-56. doi: 10.1111/j.1468-0009.2012.00670.x.
- BackgroundPawson, R. and N. Tilley, Realistic evaluation. London: Sage Publications Inc., 1997.
- BackgroundPatton, M.Q., Qualitative Research & Evaluation. 3rd ed. Thousand Oaks, CA: Sage Publications Inc., 2002.
- BackgroundCrabtree, B.F. and W.L. Miller, Doing Qualitative Research. Thousand Oaks, CA: Sage Publications Inc., 1999.
- Background: PubMed 20346624Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010 Aug;63(8):e1-37. doi: 10.1016/j.jclinepi.2010.03.004. Epub 2010 Mar 25.
- Background: PubMed 22333434Poitras ME, Fortin M, Hudon C, Haggerty J, Almirall J. Validation of the disease burden morbidity assessment by self-report in a French-speaking population. BMC Health Serv Res. 2012 Feb 14;12:35. doi: 10.1186/1472-6963-12-35.
- Background: PubMed 11032203Stewart M, Brown JB, Donner A, McWhinney IR, Oates J, Weston WW, Jordan J. The impact of patient-centered care on outcomes. J Fam Pract. 2000 Sep;49(9):796-804.
- Background: PubMed 17893379Stewart M, Brown JB, Hammerton J, Donner A, Gavin A, Holliday RL, Whelan T, Leslie K, Cohen I, Weston W, Freeman T. Improving communication between doctors and breast cancer patients. Ann Fam Med. 2007 Sep-Oct;5(5):387-94. doi: 10.1370/afm.721.
- BackgroundStewart, M., et al., The patient perception of patient-centeredness questionnaire (PPPC). Working Paper Series #04-1, April 2004.
- Background: PubMed 15725981Coleman EA, Mahoney E, Parry C. Assessing the quality of preparation for posthospital care from the patient's perspective: the care transitions measure. Med Care. 2005 Mar;43(3):246-55. doi: 10.1097/00005650-200503000-00007.
- Background: PubMed 17027221Nolte S, Elsworth GR, Sinclair AJ, Osborne RH. The extent and breadth of benefits from participating in chronic disease self-management courses: a national patient-reported outcomes survey. Patient Educ Couns. 2007 Mar;65(3):351-60. doi: 10.1016/j.pec.2006.08.016. Epub 2006 Oct 5.
- BackgroundSherer, M., et al., The self-efficacy scale: Construction and validation. Psychological Reports. 51: p. 663-671, 1982.
- Website for PACE in MMLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. De-identified subsets of data will be transferred upon request to healthcare providers at collaborating institutions under separate ethics approvals as/if required. Any transfers will be conducted by secure file transfer between encrypted devices. Any health information transferred will be de-identified.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Moira Stewart principal investigator
Western University
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing TIP / IMPACT Plus Care Coordination in people with Hypertension and Depression, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's at 9 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of Intervention Effectiveness - Change in Self-Management outcomes (time frame: T1: Initial evaluation; T2: after 4 months; T3: one year after T2;). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02742597, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2023.